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Abstract: Iron sucrose originator (ISORIG) has been used to treat iron deficiency and iron deficiency anemia for decades. 
Iron sucrose similars (ISSs) have recently entered the market. In this non-clinical study of non-anemic rats, five doses (40 
mg iron/kg body weight) of six ISSs marketed in Asian countries, ISORIG or saline solution (control) were administered 
intravenously over four weeks to compare their toxicologic effects. Vasodilatory effects, impaired renal function and 
hepatic damage were only observed in the ISS groups. Significantly elevated serum iron and transferrin saturation levels 
were observed in the ISS groups suggesting a higher release of iron resulting in higher amounts of non-transferrin bound 
(free) iron compared to ISORIG. This might explain the elevated oxidative stress and increased levels of inflammatory 
markers and antioxidant enzymes in the liver, heart and kidneys of ISS-treated animals. Physico-chemical analyses 
showed that the molecular structure of most of the ISSs differed greatly from that of the ISORIG. These differences may be 
responsible for the organ damage and oxidative stress observed in the ISS groups. Significant differences were also found 
between different lots of a single ISS product. In contrast, polarographic analyses of three different ISORIG lots were 
identical, indicating that the molecular structure and thus the manufacturing process for ISORIG is highly consistent. Data 
from this study suggest that ISSs and ISORIG differ significantly. Therefore, before widespread use of these products it 
would be prudent to evaluate additional non-clinical and/or clinical data proving the safety, therapeutic equivalence and 
interchangeability of ISSs with ISORIG. 
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INTRODUCTION 
  Iron deficiency (ID) is one of the world’s most prevalent 
nutrient deficiencies [1]. It has various causes, such as 
increased iron demands due to blood loss, growth, preg-
nancy, inadequate dietary intake due to poor nutrition, and 
inadequate gastrointestinal absorption due to malabsorption 
or interference with drugs and food components. Because 
iron-containing enzymes are essential for all major metabolic 
processes, ID can lead to inadequate synthesis of these 
essential enzymes and thus to deleterious effects on cells and 
tissues. Untreated ID can lead to iron deficiency anemia 
(IDA), a condition in which the number of red blood cells 
(RBCs), the hemoglobin (Hb) level, and the volume of 
packed RBCs in the blood are below the normal values [2, 
3]. IDA is an additional burden in numerous disease states 
including chronic heart failure (CHF) , inflammatory bowel 
disease and chronic kidney disease (CKD)  [4-9]. 
  Iron supplementation is often necessary to manage ID 
with or without anemia. The key goal is to replenish body 
iron stores and, if present, correct the Hb deficit [2]. 
Although oral iron administration is the least expensive form 
of iron therapy [5], the intravenous (i.v.) route of iron 
administration has become more favored in recent years in  
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many clinical settings due to the gastrointestinal intolerance, 
low iron delivery rates, limited absorption and prolonged 
iron store repletion times associated with oral iron 
supplements [10]. The iron preparations for i.v. administrat-
ion that have been available already for several years include 
iron sucrose, sodium ferric gluconate, and low- and high-
molecular weight iron dextran. Recently, preparations that 
allow rapid administration of high doses of iron, such as 
ferric carboxymaltose (available in various countries) and 
ferumoxytol (available in the USA), have been marketed 
worldwide. All iron complexes for i.v. administration consist 
of a polynuclear iron(III)-oxyhydroxide core shielded by a 
carbohydrate shell [11, 12]. However, they vary widely in 
their physico-chemical properties, pharmacological activity, 
and side effects [11, 13, 14]. 
  Despite the rapid recovery of the ID status in response to 
i.v. iron administration, there are potential risks associated 
with i.v. iron. Due to the risk of life-threatening/serious 
anaphylactic reactions associated with i.v. iron dextran, in 
particular high-molecular weight iron dextran, this form of 
iron therapy is not generally recommended [15-17]. 
Moreover, the more labile, low molecular weight 
compounds, such as ferric gluconate, release larger amounts 
of iron into the circulation saturating transferrin and     
generating  non-transferrin bound iron (NTBI) [14, 18]. 
NTBI is taken up unspecifically by the liver, endocrine tissue 
and heart where it may catalyze a number of reactions that 
lead to oxidative stress and tissue damage [19, 20]. The 
extent of iron release into the circulation determines the 
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minimize the amount of NTBI [21]. More stable iron 
complexes can be administered in higher doses. 
  Iron sucrose is an intravenous iron preparation that 
contains no dextran or its derivatives, and the associated 
incidence of allergic side effects has been shown to be rare 
[11, 22]. The iron sucrose originator (ISORIG,  iron sucrose 
preparation, Venofer
®, Vifor International, Switzerland) 
complex has been in clinical use for decades for the 
treatment of ID and IDA in a variety of clinical conditions 
[2]. In recent years, a number of new iron sucrose similar 
(ISS) preparations have entered the market. Their structures 
differ from that of the ISORIG complex due to different 
manufacturing processes [23]. These subtle structural 
differences may present a significant risk, raising potential 
concerns about the safety and efficacy of ISS preparations in 
clinical use. Non-clinical studies have indicated 
hemodynamic and functional differences between the ISORIG 
and ISS preparations and, in particular, a higher potential of 
ISSs to induce oxidative stress in kidneys, liver and heart 
[24, 25]. Additionally, in a recently published observational 
clinical study, switching the i.v. iron treatment of 
hemodialysis patients from ISORIG to an ISS led to a 
significant decrease in Hb levels and iron indices suggesting 
that the studied ISS preparation may not be therapeutically 
equivalent to ISORIG [26]. 
  We previously established a non-clinical model that 
allows distinguishing between the potential of ISS 
preparations to induce oxidative stress in the liver, heart and 
kidneys [24, 25]. In the present study, we used this same 
model to compare the properties of six ISS preparations in 
the Asian market with those of the ISORIG complex. 
METHODS 
Physico-Chemical Analysis 
  Physico-chemical analyses were performed by the 
Quality Control Laboratory of Vifor (International) Ltd. (St. 
Gallen, Switzerland) on the samples of the ISS preparations. 
Molecular weight distribution was measured by gel 
permeation chromatography as described previously [11, 
27]. The Fe(III)/Fe(II) reduction potentials were measured 
by polarography as described previously [11]. The turbidity 
point, pH and titratable alkalinity were assessed by methods 
described previously [27, 28]. 
Animals and Treatments 
  All experiments were approved by the Hospital Alemán 
Animal Care and the Teaching and Research Committee, and 
performed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals. Forty male and forty female 
2-month-old non-anemic Sprague-Dawley rats (Laboratory 
of Experimental Medicine, Hospital Alemán, Buenos Aires, 
Argentina) weighing 200-220 g were randomized into eight 
groups (n  = 10/group) with an equal male-female 
distribution. The control group received isotonic saline 
solution and the ISORIG group received iron sucrose 
[Venofer
®, LOT 517100, Vifor (International), Switzerland]. 
The ISS groups received either ISSFERP (Ferplex
® SS, LOT 
H3797, Himont Pharmaceuticals, Lahore, Pakistan), ISSFERI 
(Ferijet, LOT 024-Y, Akson Pharmaceuticals, Azad 
Kashmir, Pakistan), ISSFERO (Ferosoft
® S, LOT 6016, Hilton 
Pharma Ltd., Karachi, Pakistan), ISSENCI (Encifer
®, Emcure 
Pharmaceuticals Ltd., Pune, India), ISSBACK (Fe-Back, Nang-
Kuang Pharmaceutical Co. Ltd., Tainan Hsien, Taiwan) or 
ISSLIB (Fe-Lib, LOT A5015, Advanced International 
Pharmaceutical Nanotech Inc., Taiwan). 
  Rats were housed in metabolic cages in a temperature-
controlled room (22 ± 2 °C) subject to 12 h light/dark cycles 
(07.00-19.00). All animals had free access to tap water and 
were fed standard rat chow (16-18% protein, Cooperación, 
Argentina) ad libitum throughout the study. Rats received a 
single i.v. dose by tail vein injection of the corresponding 
iron compound (40 mg/kg body weight) or control solution 
(equivalent volume) at the same time every 7 days for 4 
weeks (a total of five administrations on days 0, 7, 14, 21 
and 28). Treatment doses were adjusted each week according 
to the body weight of each animal. 
  Blood samples were obtained for biochemical assessment 
of Hb, serum iron and transferrin saturation (TSAT) 24 h 
after an i.v. iron treatment on days 1, 8, 15, 22 and 29. Urine 
was collected in each group for 24 h after each i.v. injection 
with methods described previously [29]. The rats were 
sacrificed on day 29 by subtotal exsanguination under 
anesthesia (sodium thiopental, 40 mg/kg body weight, 
intraperitoneal) according to institutional guidelines for 
animal care and use. Previously, blood samples were 
obtained for biochemistry determination. The liver, heart and 
kidneys of each rat were perfused with ice cold saline 
solution through the abdominal aorta until they were free of 
blood and then removed for oxidative stress evaluation, 
microscopy and immunohisto-chemical study. 
Blood Pressure Measurement 
  Systolic blood pressure (SBP) was measured by tail-cuff 
plethysmography at baseline (day 0) and 24 h after each i.v. 
iron administration (days 1, 8, 15, 22, and 29). Cuff pressure 
was determined by a Pneumatic Pulse Transducer using a 
Programmed electro-sphygmomanometer PE-300 (Narco 
Bio-Systems, Austin, Texas, USA); rats were restrained in a 
plastic chamber without anesthesia. Pulses were recorded on 
a Physiograph MK-IIIS (Narco Bio-Systems, Austin, Texas, 
USA) and a minimum of three measurements were taken at 
each session. The SBP was calculated as an average of the 
three readings [29, 30]. 
Biochemical Procedures 
  Blood samples were collected from the tail vein in 
capillary tubes for biochemistry determination after 14 h of 
fasting. Hb concentration was determined by SYSMEX XT 
1800i (Roche Diagnostic GmbH, Mannheim, Germany). 
Serum iron was determined by radial immunodiffusion 
(Diffu-Plate, Biocientifica S.A., Buenos Aires, Argentina) 
and TSAT was obtained using traditional chemical methods. 
Liver enzymes, including aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) and alkaline phosphatase 
(ALP), were assessed in the blood samples by colorimetric 
and ultraviolet (UV) methods using an Autoanalyzer 
Modular P800 with corresponding reagents (Roche 
Diagnostic GmbH, Mannheim, Germany). Aliquots of urine 
were assessed for creatinine with the enzymatic UV method 
(Randox Laboratories Ltd., Crumlin, Northern Ireland). 
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formula, and proteinuria was determined using the 
sulfosalicylic acid method. 
Evaluation of Oxidative Stress Parameters in Liver, 
Heart and Kidney 
  Samples of the whole liver, heart and kidney were 
homogenized (1:3, w:v) in ice cold 0.25 M sucrose solution. 
Glutathione (GSH) levels were determined in the 10,000  g 
supernatant by methods described previously [31, 32]. 
Further samples of the corresponding perfused tissues were 
homogenized (1:10, w:v) in 0.05 M sodium phosphate buffer 
(pH 7.4) and used for the determination of malondialdehyde 
to evaluate lipid peroxidation by thiobarbituric acid reactive 
species (TBARS). The remaining homogenate was 
centrifuged at 4 °C for 15 min at 9,500  g and the 
supernatant was used to measure catalase activity. The 
remaining tissue samples were homogenized (1:3, w/v) in ice 
cold sucrose solution (0.25 M). The supernatant obtained 
after centrifugation at 105,000  g for 90 min was used to 
measure Cu, Zn superoxide dismutase (Cu, Zn-SOD) and 
glutathione peroxidase (GPx) activity. Enzyme units (U) 
were defined previously [14]. Specific activity was 
expressed as U/mg protein. 
Light Microscopy and Immunohistochemical Study 
  Decapsulated kidney, liver and heart samples were cut 
longitudinally, fixed in phosphate-buffered 10% 
formaldehyde (pH 7.2) and embedded in paraffin. Three-
micron sections were cut and stained. All observations were 
made with a light microscope Nikon E400 (Nikon 
Instrument Group, Melville, New York. USA) [24, 33, 34]. 
  Immunolabeling of specimens was carried out using a 
modified avidin-biotin-peroxidase technique (Vectastain 
ABC kit, Universal Elite, Vector Laboratories, CA, USA) as 
described previously [14]. Tissue ferritin was quantified with 
antiferritin monoclonal antibody (Biogen, San Román, 
California, USA). Pro-inflammatory markers were quantified 
with monoclonal antibodies against rat tumor necrosis 
factor-alpha (TNF-) (R&D Systems, Minneapolis, MN, 
USA) and interleukin-6 (IL6) (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) at dilutions of 1:50 and 1:100, 
respectively (PBS diluting agent) [29, 35]. 
Morphometric Analysis 
  Histological sections were studied in each animal with an 
image analyzer (Image-Pro Plus version 4 for Windows, 
Media Cybernetics LP, Silver Spring, MD, USA) as 
described previously [14].  
Statistical Methods 
  Values are expressed as mean ± SD. All statistical 
analyses were performed using absolute values and 
processed through GraphPad Prism version 5.01 for 
Windows (GraphPad Software, Inc. San Diego, CA, USA). 
For parameters with a Gaussian distribution, comparisons 
among groups were performed using analysis of variance 
(ANOVA) and for parameters with a non-Gaussian 
distribution using Kruskal-Wallis test (non-parametric 
ANOVA) and Dunn’s multiple comparison test. A value of 
p<0.05 was considered significant. 
RESULTS 
Physico-Chemical Analyses 
  The physico-chemical analyses of the studied ISS 
preparations showed clearly that, except for ISSFERP, these 
products do not comply with the specifications of ISORIG 
[27]. All ISSs, except for ISSFERP, had lower titratable 
alkalinity and out of range turbidity point (Table 1). In 
addition, ISSFERI, ISSBACK, and ISSLIB had a very high 
molecular weight. ISSFERI and ISSFERO also had a lower pH 
Table 1.  Characteristics, pH, Titratable Alkalinity, Turbidity Point, and Molecular Weight of the Six Asian ISS Preparations 
Compared with the Originator Iron Sucrose (ISORIG) and the Pharmacopeia (USP). (Studies Performed by the Quality 
Control Laboratory of Vifor (International), St. Gallen, Switzerland) 
Parameter USP
a  ISORIG  ISSFERP  ISSFERI  ISSFERO ISSENCI ISSENCI ISSBACK ISSBACK ISSLIB 
Lot  - 517100  H3797 024-T  6016  LHA04003  LHA05005  F5097 D5064 A5015 
Characteristics  - 
Dark 
brown, 
opaque 
aqueous 
solution 
Complies Complies Complies Complies Complies Complies Complies Complies 
pH  10.5-11.1 10.9  10.5  10.4 9.8 10.6 10.8 10.8 10.5 10.6 
Titratable 
alkalinity (ml) 
0.5-0.8 0.8  0.55  0.4 0.18  0.33 0.4 0.46 0.38 0.37 
Turbidity point  4.4-5.3 4.9  5.1  9.7 4.2 5.8 6.4  N/A
b N/A
b 5.33 
Mw (Da)  34,000-60,000  45,700  50,600  215,000  39,200 50,500 46,400  293,000 162,000 246,000 
Mn (Da)  24,000 33,900  36,100 85,200 31,300 35,100 34,200  175,000  93,300  151,000 
P  1.7 1.3 1.4  2.52  1.25 1.44 1.36 1.67 1.74  1.63 
a [27] 
b Starting solution turbid 
N/A, not available; Mw (Da), weight average molecular weight in Dalton; Mn (Da), number average molecular weight in Dalton; P = ratio Mw/Mn Differences Between Intravenous Iron Sucrose Preparations in a Rat Model  Inflammation & Allergy - Drug Targets, 2012, Vol. 11, No. 1    69 
than ISORIG. Interestingly, great variations in some of the 
physico-chemical parameters were also observed between 
the different lots of the two ISSs (ISSENCI and ISSBACK) that 
were analyzed. 
 The reduction potentials were determined by 
polarography and are measured vs. Ag/AgCl 3M KCl, if not 
otherwise specified. The iron(III)/iron(II) reduction 
potentials varied considerably among the different 
investigated ISSs. The reduction potential of ISSFERP was the 
only one of the studied ISSs that complied with the reference 
value for iron sucrose and also the shape of its polarogram 
was found to be identical to that of ISORIG (Fig. 1). The 
reduction potentials of ISSBACK and ISSLIB were not 
determinable due to low solubility of these compounds. In 
addition, the shapes of the polarograms for these ISSs were 
different from that of ISORIG, confirming the dissimilarities 
between the structures of these ISSs and that of the ISORIG 
complex (Fig. 1). The reduction potentials of ISSFERI, 
ISSFERO and ISSENCI did not match the specifications for iron 
sucrose (-750 ± 50 mV) [27]. The polarogram of ISSFERI 
revealed two distinct Fe(III)/Fe(II) transitions at -495 and -
765 mV. ISSFERO had a reduction potential of -566 mV, 
whereas ISSENCI had different values depending on the 
analyzed lot (-565 and -534 mV for lot LHA04003 and 
LHA05005, respectively). In contrast, polarograms of three 
randomly chosen lots of ISORIG had an identical shape and 
complied with the reference specification, reflecting the high 
consistency of the manufacturing process and thus the 
structure of the ISORIG complex (Fig. 1). 
Non-Clinical Study 
  Throughout the non-clinical study, no significant 
differences were observed in Hb concentrations between the 
i.v. iron-treated and control groups, as expected for non-
anemic rats (Table 2). Biochemical analysis revealed that 
serum iron concentration and TSAT levels were significantly 
elevated (p<0.01) in animals from the ISS groups and the 
ISORIG group compared to control group on days 1, 8 and 29 
(Table  2).  The ISORIG group showed significantly lower 
values (p<0.01) in both serum iron concentration and 
percentage TSAT compared to the ISS groups on days 1, 8 
and 29. 
  All ISS groups (ISSFERP, ISSFERI, ISSFERO, ISSENCI, 
ISSBACK, ISSLIB) presented a significant decrease in SBP 
throughout the study compared to the control and ISORIG 
groups (p<0.01) (Table 3); there were no significant 
differences between the ISS groups themselves.  
  CrCl was significantly reduced in rats from all of the ISS 
groups on days 1, 8 and 29 compared with the ISORIG and 
control groups (p<0.01) (Table 4), whereas the values 
between the ISORIG and control group did not differ 
significantly. All ISS groups showed significant proteinuria 
on days 1, 8 and 29 (p<0.01) compared with the ISORIG and 
control groups, which showed no differences throughout the 
study (Table 4). Assessment of liver function showed that 
AST, ALT and ALP levels were significantly increased 
(p<0.01) in all ISS groups on days 1, 8 and 29 compared 
with ISORIG and control groups (Fig. 2A-C). Significant 
differences, although modest (p<0.05), were observed 
between the ISORIG group and the control group on days 1 
and 8. However, there was no marked difference between 
these groups on day 29. 
  The liver, heart and kidney tissues of all the ISS groups 
showed a significant increase (p<0.01) in malondialdehyde 
(TBARS), catalase, GPx, and Cu, Zn-SOD levels and a 
significant decrease (p<0.01) in GSH level when compared 
with the ISORIG and control groups on day 29 (Fig. 3A-E). 
The ISORIG group showed only modest non-significant 
increases in the levels of malondialdehyde, catalase, GPx, 
and Cu, Zn-SOD in the liver and a modest non-significant 
decrease in the GSH levels in the liver, heart and kidneys 
compared to the control group on day 29. Other oxidative 
stress parameters did not differ between the ISORIG group and 
the control group in heart or kidneys at the end of the study. 
  On day 29, microscopy studies of the liver showed 
significantly more (p<0.01) positive staining for iron 
(Prussian blue) in the Kupffer cells, sinusoidal epithelial 
cells and hepatocytes in all ISS groups compared to the 
ISORIG group. The ISORIG group had iron deposits only in the 
Kupffer cells and displayed a significantly (p<0.01) greater 
area for ferritin staining in the liver compared to the ISS and 
control groups (Table 5). 
  On day 29, cardiomyocytes of all ISS groups showed a 
significantly larger (p<0.01) area for iron staining (Prussian 
blue) compared to that of the cardiomyocytes of the ISORIG 
and control groups. Only small ferritin deposits were 
observed in all of the ISS groups, whereas ferritin deposits 
were significantly larger (p<0.01) in the ISORIG group (Table 
5). 
  A significant (p<0.01) positive staining for iron (Prussian 
blue) was detected in the proximal tubular epithelial cells of 
all the ISS groups compared with the ISORIG and control 
groups on day 29. The ISORIG group showed a larger area for 
ferritin deposits in the proximal tubular epithelial cells 
compared to all of the ISS and control groups (Table 5). 
  Upon completion of the experiments, the levels of both 
inflammatory markers TNF- and IL6 were significantly 
increased (p<0.01) in the liver, heart and kidney samples of 
the ISS groups compared with the ISORIG and control groups 
(Figs. 4 and 5). 
DISCUSSION 
  The iron sucrose originator complex has been in clinical 
use for decades representing a good therapeutic option for 
correction of ID and IDA in more than 80 countries [2]. 
Together with erythropoiesis-stimulating agents it has 
become an integral part of IDA management associated with 
various clinical conditions. Clinical experience with ISORIG is 
based on patient exposure of more than 12 million patient 
years (as of 30 June 2011). ISORIG is regarded as a product 
with a good clinical profile [36, 37], particularly as it carries 
a low potential risk of hypersensitivity reactions [38]. 
  Iron sucrose is a complex made of a polynuclear 
iron(III)-oxyhydroxide core stabilized by a sucrose ligand 
[39]. As such, it is a polymeric compound which belongs to 
the class of non-biological complex drugs and therefore is 
very different from conventional small molecule active 
pharmaceutical ingredients (APIs). Polymeric compounds 
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different molecular weights and are characterized by a 
distinct molecular weight distribution. Thus, characterization 
of polymeric compounds requires a set of analytical methods  
different from those used for conventional APIs. Due to the 
complexity of the process to synthesize iron sucrose, the 
manufacturing process largely defines the quality of the 
product [23, 39]. 
  Recently, a number of ISS preparations have entered the 
market [23-25]. However, little is known about their safety 
profile as non-clinical or clinical data are not largely 
available. In this study, the toxicologic effects of six ISS 
preparations marketed in Asian countries (ISSFERP, ISSFERI, 
 
 
Fig. (1). Polarograms of (A) ISSFERP, (B) ISSBACK (Lot 5064), (C) ISSLIB, and (D-F) three randomly chosen lots of ISORIG. (Studies 
performed by the Quality Control Laboratory of Vifor (International) Ltd., St. Gallen, Switzerland.) 
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Fig. (2). (A) Aspartate aminotransferase  (AST), (B) alanine 
aminotransferase (ALT) and (C) alkaline phosphatase (ALP) after 
weekly i.v. administration (40 mg iron /kg body weight or 
equivalent volume) in the ISORIG, ISS and control groups over a 4-
week period. 
 
ISSFERO, ISSENCI, ISSBACK, ISSLIB) on hemodynamic and 
oxidative stress parameters, inflammatory markers, tissue 
histologies and biochemical processes were evaluated versus 
ISORIG and control. 
  Similar to the results of the current study, our previous 
studies showed that the ISSs we investigated differed from 
ISORIG in terms of their stability and molecular structure [24, 
25]. These structural differences are indicative of differences 
in the manufacturing process [23] and might be responsible 
for the negative effects of various ISS preparations that we 
have observed in our non-clinical studies [24, 25]. 
Interestingly, these subtle structural differences can escape 
physico-chemical characterization [23]. Recently, Meier et 
al. published a study in which they performed a toxicological 
characterization of a new ISS using a simplified version of 
the rat model used in the present study (shortened to an 
eight-day protocol).  In contrast to the results presented here, 
their study found that the ISS had physico-chemical and 
toxicological properties comparable to those of ISORIG [40]. 
However, in a previous non-clinical study, we identified an 
ISS that had physico-chemical properties in compliance with 
the USP values for iron sucrose, but nevertheless induced a 
higher degree of oxidative stress and tissue damage than 
ISORIG [41]. Thus, even full compliance with USP-specified 
physico-chemical parameters does not ensure a complete 
characterization of an iron sucrose complex. Moreover, an 
observational clinical study in hemodialysis patients recently 
demonstrated that switching from ISORIG to an ISS led to a 
significant decrease in Hb levels and iron indices [26]. These 
findings highlight the increased need for appropriate clinical 
and non-clinical studies to determine the toxicological and 
clinical profiles of these ISS products prior to their approval 
[23, 42]. Consistent with this recommendation, the European 
Medicines Agency (EMA) recently recommended that non-
clinical comparative assessments of target tissue 
concentrations should be performed in support of the 
evaluation of copies of intravenous nanoparticle iron 
medicinal products compared to the originator. In making 
their recommendation, the EMA recognized that assessments 
in humans based on plasma concentrations alone may not be 
Table 2.  Hemoglobin (Hb), Serum Iron and Transferrin Saturation (TSAT) 
Mean ± SD  ISSFERP 
(n = 10) 
ISSFERI 
(n = 10) 
ISSFERO 
(n = 10) 
ISSENCI 
(n = 10) 
ISSBACK 
(n = 10) 
ISSLIB 
(n = 10) 
ISORIG 
(n = 10) 
Control 
(n = 10) 
Day 1 
Hb (g/dL)  15.8 ± 0.2  15.8 ± 0.1  16.0 ± 0.1  16.1 ± 0.1  15.9 ± 0.2  15.8 ± 0.2  15.9 ± 0.2  15.8 ± 0.5 
Serum iron (g/dL)  559.1 ± 60.2  563.2 ± 55.3  539.0 ± 59.1  542.2 ± 50.0  549.9 ± 47.1  555.1 ± 60.0  360.0 ± 42.0
#  309.9 ± 15.0* 
TSAT (%)  86.9 ± 4.3  90.0 ± 4.1  87.7 ± 5.0  86.8 ± 5.9  86.9 ± 6.0  89.2 ± 3.9  73.2 ± 6.2
#  45.1 ± 3.8* 
Day 8 
Hb (g/dL)  16.2 ± 0.1  16.4 ± 0.2  16.3 ± 0.2  16.1 ± 0.1  16.4 ± 0.1  16.4 ± 0.2  16.4 ± 0.2  15.9 ± 0.4 
Serum iron (g/dL)  489.0 ± 52.0  500.0 ± 66.0  499.0 ± 58.0  488.3 ± 45.0  500.1 ± 32.0  479.9 ± 52.0  398.0 ± 33.0
#  318.0 ± 18.0* 
TSAT (%)  85.9 ± 3.0  87.0 ± 5.2  89.9 ± 6.1  89.4 ± 6.0  88.3 ± 4.9  88.2 ± 5.2  69.9 ± 5.5
#  48.3 ± 5.9* 
Day 29 
Hb (g/dL)  16.4 ± 0.2  16.5 ± 0.2  16.5 ± 0.1  16.5 ± 0.2  16.5 ± 0.2  16.5 ± 0.1  16.5 ± 0.2  16.0 ± 0.5 
Serum iron (g/dL)  478.1 ± 45.2  458.9 ± 60.0  486.3 ± 43.0  453.7 ± 41.1  469.5 ± 56.2  487.9 ± 39.9  395.7 ± 21.0
#  301.0 ± 10.8* 
TSAT (%)  84.4 ± 4.2  89.9 ± 6.1  88.9 ± 5.3  89.0 ± 5.7  84.8 ± 5.1  86.6 ± 4.4  70.1 ± 4.5
#  47.2 ± 4.6* 
*p < 0.01 versus all groups 
#p < 0.01 versus ISSFERP, ISSFERI, ISSFERO, ISSENCI, ISSBACK, ISSLIB 
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sufficient to ensure a comparable safety and efficacy profile 
of these products [42]. 
  In the present study, the results of the physico-chemical 
analysis of the investigated ISSs showed that only one of 
them, namely ISSFERP, complied with the USP values for 
iron sucrose. Within the other ISSs, significant fluctuations 
in the physico-chemical parameters from the reference 
values for iron sucrose were evident. In addition, differences 
in the physico-chemical parameters were also seen between 
the different lots of ISSENCI and ISSBACK. Clearly, the 
manufacturing processes of these two ISSs are not well 
controlled and thus lead to products with variable structure, 
stability and quality. In contrast, the manufacturing process 
of ISORIG is highly consistent, as shown by the identical 
polarograms of three randomly chosen lots. The 
polarographic analysis does not only indicate the potential of 
a complex to undergo redox cycling (reduction potential), 
but it is also considered as a fingerprint for the structure of 
the complex. Lack of physico-chemical identity with the 
originator demonstrates that ISSFERI, ISSFERO, ISSENCI, 
ISSBACK, and ISSLIB do not possess pharmaceutical 
equivalence to ISORIG. 
 According to the non-clinical analysis, initial 
observations of the effects of the ISS compounds on SBP 
revealed marked hypotension. This was evident throughout 
the 4-week study in all ISS-treated animals, whereas SBP in 
the ISORIG and control groups was not affected. The 
vasodilatory effects associated with ISS administration 
highlight a potentially significant risk factor for translation to 
clinical practice and are consistent with the hypotensive 
effects reported in animals receiving ISS preparations in 
previous studies [24, 25]. 
  Renal function, explored by CrCl, was not affected in rats 
treated with ISORIG, but it was significantly reduced in the 
ISS groups. The reduced CrCl was accompanied by a 
marked proteinuria, indicating not only impaired renal 
function but also some disturbance in glomerular epithelial 
cells (podocytes) and tubular epithelial cells, in ISS-treated 
animals. As in our previous studies [24, 25], these results 
suggest that ISS preparations have more deleterious effects 
on the kidneys compared to the ISORIG compound. Also 
parallel to our previous studies, ISS induced hepatic damage 
was indicated by elevated levels of liver enzymes (ALT, 
AST and ALP) in the ISS groups compared to the ISORIG and 
control groups throughout the study [24, 25, 33]. The hepatic 
injury associated with elevated levels of liver enzymes in the 
blood may raise concerns regarding the use of ISS 
compounds in the clinical setting. 
Table  3.  Systolic Blood Pressure (mean ± SD) After Weekly i.v. Administration (40 mg Iron/kg Body Weight or Equivalent 
Volume) in ISS, ISORIG and Control Groups Over a 4-Week Period 
 
Day 
ISSFERP 
(n = 10) 
ISSFERI 
(n = 10) 
ISSFERO 
(n = 10) 
ISSENCI 
(n = 10) 
ISSBACK 
(n = 10) 
ISSLIB 
(n = 10) 
ISORIG 
(n = 10) 
Control 
(n = 10) 
0  118.1 ± 2.4  119.0 ± 2.9  118.1 ± 2.4  119.0 ± 2.9  118.1 ± 2.3  119.1 ± 2.9  118.9 ± 2.2  118.9 ± 1.9 
1  112.3 ± 1.9  111.0 ± 0.1  112.3 ± 1.9  114.1 ± 1.9  112.3 ± 1.9  112.0 ± 1.9  116.2 ± 2.0
#  120.2 ± 0.5* 
8  111.4 ± 1.7  112.0 ± 3.1  114.7 ± 1.7  113.6 ± 3.1  114.7 ± 1.7  110.1 ± 3.1  117.8 ± 2.8
#  119.8 ± 2.1
# 
15  112.6 ± 1.8  111.1 ± 2.4  114.9 ± 1.8  114.1 ± 2.4  116.8 ± 1.8  114.7 ± 2.4  118.0 ± 2.2
#  120.3 ± 2.1
# 
22  113.7 ± 2.0  114.2 ± 2.5  114.5 ± 2.0  112.1 ± 2.5  114.5 ± 2.0  113.9 ± 2.5  119.4 ± 1.9
#  120.3 ± 2.0
# 
29  115.1 ± 1.8  114.8 ± 3.0  113.6 ± 2.5  114.7 ± 2.6  113.7 ± 2.0  113.8 ± 3.0  121.2 ± 2.6
#  122.1 ± 2.4
# 
*p< 0.01 versus all groups 
#p< 0.01 versus ISSFERP, ISSFERI, ISSFERO, ISSENCI, ISSBACK, ISSLIB 
 
Table  4.  Creatinine Clearance and Proteinuria After Weekly i.v. Administration (40 mg Iron/kg Body Weight or Equivalent 
Volume) in the ISS, ISORIG and Control Groups Over a 4-Week Period 
 
Day 
ISSFERP 
(n = 10) 
ISSFERI 
(n = 10) 
ISSFERO 
(n = 10) 
ISSENCI 
(n = 10) 
ISSBACK 
(n = 10) 
ISSLIB 
(n = 10) 
ISORIG 
(n = 10) 
Control 
(n = 10) 
CrCl 
1  2.4 ± 0.1  2.3 ± 0.1  2.4 ± 0.2  2.1 ± 0.1  2.2 ± 0.1  2.3 ± 0.2  2.7 ± 0.1
#  2.8 ± 0.1* 
8  3.3 ± 0.1  2.2 ± 0.1  2.3 ± 0.1  2.2 ± 0.2  2.3 ± 0.2  2.3 ± 0.1  2.8 ± 0.1
#  2.9 ± 0.1
# 
29  2.1 ± 0.1  2.2 ± 0.1  2.2 ± 0.1  2.3 ± 0.2  2.1 ± 0.2  2.4 ± 0.2  2.7 ± 0.1
#  2.9 ± 0.1
# 
Proteinuria 
1  19.2 ± 5.5  22.1 ± 6.2  16.9 ± 7.1  18.5 ± 7.9  17.4 ± 5.8  19.9 ± 5.8  2.0 ± 1.3
#  1.2 ± 2.0
# 
8  21.9 ± 6.6  26.3 ± 7.7  27.3 ± 9.9  33.2 ± 5.8  22.9 ± 4.9  25.1 ± 4.1  5.7 ± 2.4
#  4.1 ± 2.1
# 
29  35.4 ± 7.0  31.8 ± 8.2  30.7 ± 5.9  39.4 ± 8.2  35.1 ± 5.8  29.8 ± 7.9  6.3 ± 3.0
#  3.8 ± 3.0
# 
*p< 0.01 versus all groups 
#p< 0.01 versus ISSFERP, ISSFERI, ISSFERO, ISSENCI, ISSBACK, ISSLIB  Differences Between Intravenous Iron Sucrose Preparations in a Rat Model  Inflammation & Allergy - Drug Targets, 2012, Vol. 11, No. 1    73 
  The stability of an iron complex depends on the exact 
structure of the complex and, in particular, on the interaction 
between the polynuclear iron(III)-hydroxide core and the 
surrounding carbohydrate [11]. As expected, in this study, all 
i.v. iron treated animals showed a significant increase in 
serum iron and TSAT levels. However, the administration of 
the ISS preparations resulted in significantly higher serum 
iron and TSAT levels than administration of the ISORIG. 
Serum iron reflects the balance of iron flow in and out of the  
plasma pool [2, 43]. Therefore, higher serum iron levels 
induced by the ISS preparations suggest a quicker release of 
iron from these carbohydrate complexes causing transfer 
mechanisms of iron to be saturated, which leads to the 
generation of non-transferrin bound iron (NTBI). The more 
labile compounds release iron more quickly and to a greater 
extent, saturating transferrin, generating higher amounts of 
NTBI, and possibly causing oxidative stress, endothelial 
damage, inflammation and hemodynamic alterations [44]. 
 
Fig. (3). (A) Thiobarbituric acid reactive species (TBARS), (B) catalase, (C) Cu,Zn-superoxide dismutase (Cu,Zn-SOD), (D) glutathione 
peroxidase (GPx), (E) glutathione (GSH) in liver, heart and kidney homogenates after i.v. administration (40 mg iron /kg body weight or 
equivalent volume) in the ISORIG, ISS and control groups on day 29. 
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  NTBI is taken up unspecifically by the liver, endocrine 
tissue and heart where it may further catalyze reactions 
leading to oxidative stress and tissue damage [19, 20]. 
Therefore, it is not surprising that the markers for oxidative 
stress and the levels of antioxidant enzymes were 
significantly increased in the liver, heart and kidney tissues 
in all ISS-treated animals compared to the ISORIG-treated 
animals and the control group throughout the study. 
Furthermore, oxidative stress can also increase the risk of 
endothelial damage and inflammation [44, 45]. The levels of 
both pro-inflammatory markers TNF- and IL6 were 
substantially higher in the ISS groups relative to IS ORIG 
and control groups at the end of the study. These results 
further confirm that ISORIG has a lower potential to induce 
oxidative stress and inflammation in this non-clinical model. 
From a clinical point of view, these findings may be 
important since i.v. iron therapy is often used to treat ID or 
IDA in CKD, CHF and cancer patients, who are already 
subject to increased levels of oxidative stress. This is 
particularly relevant for hemodialysis patients, who 
necessitate frequent administration of i.v. iron.  
 In  vitro experiments have also shown differences among 
commonly used i.v. iron preparations. In particular, there is 
accumulating evidence that depending on the stability and 
the redox properties of the iron complex, iron preparations 
can influence cytokine activation, reactive oxygen species 
generation, and lymphocyte survival to different degrees [46-
48].   
  In this study, the iron(III)/iron(II) reduction potentials of 
the different ISSs, except ISSFERP, showed great variations 
from the USP values for iron sucrose and that of ISORIG. The 
reduction potentials of ISSFERI, ISSFERO and ISSENCI were 
more positive than that of ISORIG, suggesting that these ISS 
preparations may undergo redox cycling under physiological  
conditions and thus cause oxidative stress. Previous studies 
also showed that other ISSs with a more positive reduction 
potential than that of ISORIG induced oxidative stress in an 
analogous non-clinical model [24, 25]. Interestingly, ISSFERI 
was found to exhibit two distinct reduction potentials 
whereas ISSENCI had different reduction potentials depending 
on the analyzed lot.  
  Cellular uptake, transient storage and subsequent 
utilization of iron  are  influenced in part by the type of iron 
preparation administered and in part by the dosage, treatment 
regimen and physiological status of the patient [49]. Iron 
from the ideal iron preparation is transiently deposited in the 
reticuloendothelial system and not in the parenchyma of the 
liver [11]. ISORIG shows exactly this pattern, with a more 
pronounced increase in iron and ferritin in the liver, and only 
a smaller increase relative to the control group in the heart 
and kidney. The presence of NTBI and oxidative stress in the 
livers of animals of the ISS groups was consistent with 
positive staining for iron not only in the Kupffer cells but 
also in the surrounding tissue. Accordingly, ferritin deposits, 
in particular in the liver, were reduced in the ISS groups 
suggesting that iron was stored in other cellular 
compartments rather than in the endogenous storage protein 
ferritin found predominantly in the liver.  
  The data from this study along with the results from three 
additional ISSs tested in two previously published studies 
[24, 25] show that various ISSs have slightly different 
toxicological patterns. In particular, the organs analyzed 
(liver, heart, and kidney) were not always affected to the 
same extent. For instance, most ISSs from this study showed 
a more pronounced effect on the kidneys (as seen from the 
proteinuria, IL6, iron and ferritin data), whereas significant 
differences in liver toxicity have been observed for two ISSs 
tested in a previous study [24]. 
  Despite the significant differences that have been 
observed between ISORIG and the investigated ISSs, the 
clinical relevance of the toxicological model used in this 
study and the significance of the results obtained require 
further discussion. The i.v. administration route adopted in  
this study is similar to clinical practice since iron sucrose can 
be given by both injection as well as infusion. However, the 
single iron doses used in the clinic are usually lower than 
those used in this study. Regarding oxidative stress, several  
clinical studies have investigated changes in biomarkers of 
oxidative stress after i.v. iron administration and 
demonstrated an inverse relation between the stability of the 
iron complexes and the induction of oxidative stress [46, 47,  
 
Table  5.  Prussian Blue Staining and Ferritin Immunostaining in the Liver, Heart and Kidney Samples of the Six Asian ISS 
Groups, the ISORIG Group, and the Control Group on Day 29 
 
Mean ± SD 
ISSFERP 
(n = 10) 
ISSFERI 
(n = 10) 
ISSFERO 
(n = 10) 
ISSENCI 
(n = 10) 
ISSBACK 
(n = 10) 
ISSLIB 
(n = 10) 
ISORIG 
(n = 10) 
Control 
(n = 10) 
Prussian blue (% positive staining/area) 
Liver  6.8 ± 2.0  15.1 ± 3.2  14.6 ± 2.2  14.2 ± 2.6  14.7 ± 2.8  14.9 ± 1.8  7.4 ± 2.0
#  1.2 ± 0.5* 
Heart  4.1 ± 0.7  3.8 ± 0.6  4.0 ± 0.7  3.6 ± 0.8  3.9 ± 0.7  3.7 ± 0.8  1.1 ± 0.3
#  0.2 ± 0.1* 
Kidney  7.1 ± 1.0  6.2 ± 1.2  6.6 ± 1.5  6.4 ± 1.8  6.8 ± 1.3  6.3 ± 1.4  3.1 ± 0.8
#  1.3 ± 0.1* 
Ferritin (% positive staining/area) 
Liver  7.3 ± 2.0  6.9 ± 1.7  6.8 ± 1.4  7.5 ± 2.0  7.5 ± 1.1  7.1 ± 2.0  15.2 ± 1.4
#  2.1 ± 0.6* 
Heart  1.8 ± 0.4  1.7 ± 0.3  1.9 ± 0.4  1.7 ± 0.5  1.4 ± 0.5  1.6 ± 0.6  3.1 ± 0.4
#  0.2 ± 0.1* 
Kidney  3.6 ± 0.5  3.0 ± 0.5  2.7 ± 0.7  3.3 ± 0.5  3.6 ± 0.3  3.4 ± 0.6  6.1 ± 0.7
#  0.2 ± 0.1* 
* p < 0.01 versus all groups  
# p < 0.01 versus ISSFERP , ISSFERI, ISSFERO, ISSENCI, ISSBACK, ISSLIB Differences Between Intravenous Iron Sucrose Preparations in a Rat Model  Inflammation & Allergy - Drug Targets, 2012, Vol. 11, No. 1    75 
 
Fig. (4). Bar chart and corresponding micrographs showing tumor 
necrosis factor-alpha (TNF-) immunostaining in liver, heart and 
kidney samples taken from the ISORIG, ISS and control groups on 
day 29. 
 
50-52]. Accordingly, differences in the physicochemical 
properties and stability of ISSs compared to ISORIG as 
demonstrated in the present study may also be expected to 
affect oxidative stress levels in the clinical setting. In 
addition, differences observed in the present study in the 
distribution of iron that resulted in the deposition of iron in 
the parenchymal tissues instead of the reticuloendothelial 
system may lead to a decrease in the amount of iron that is 
available for effective erythropoiesis and, therefore, partly 
explain the recently published clinical observation of a lower 
efficacy of an ISS in maintaining Hb and iron status 
parameters in hemodialysis patients after the switch from 
ISORIG [26].  
 
Fig. (5). Bar chart and corresponding micrographs showing 
interleukin-6 (IL6) immunostaining in liver, heart and kidney 
samples taken from the ISORIG, ISS and control groups on day 29. 
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  Overall, the significant differences observed for most of 
the ISSs compared to the ISORIG, raise potential safety 
concerns on the interchangeabilty of these i.v. iron 
preparations and suggest that careful non-clinical and clinical 
evaluations of the safety and efficacy of ISSs should be 
performed before exposing vulnerable patients to potential 
additional sources of oxidative stress and inflammation.  
CONCLUSION 
  The results from this study support those of previous 
comparative non-clinical ISS studies highlighting the extent 
and severity of the effects that variations in manufacturing 
procedures for iron sucrose preparations can cause. The 
physico-chemical characterization demonstrated that five of 
the six studied ISS preparations do not comply with the 
specifications of the USP Monograph for iron sucrose 
injection. Differences of variable degree in the molecular 
structures of these compounds arise from variations in the 
manufacturing process and may be responsible for the toxic 
effects that were observed in this non-clinical model. In 
contrast, polarographic analyses of three different ISORIG lots 
were identical and thus confirmed the high degree of 
consistency in the manufacturing process of ISORIG. 
Interestingly, ISSFERP, which met the physico-chemical 
reference values for iron sucrose, induced an elevated level 
of oxidative stress compared to ISORIG. Thus demonstrating 
that similar physico-chemical properties do not ensure 
similar toxicological effects. The reduced ability of the 
investigated ISSs to provide iron in the form that can be 
stored in ferritin, as well as the increased iron release 
indicated by higher oxidative stress marker levels, led to 
deleterious effects on hemodynamic, functional and 
inflammatory responses. In conclusion, all of the studied ISS 
preparations marketed in Asian countries showed different 
toxicological effects in rats compared to the iron sucrose 
originator and therefore, before administering such products 
in the clinical setting, it is suggested that therapeutic 
equivalence to the originator product ought to be proved to 
avoid exposing patients to potentially less safe preparations. 
ABBREVIATIONS 
ALP =  Alkaline  phosphatase 
ALT =  Alanine  aminotransferase 
AST =  Aspartate  aminotransferase 
CHF  =  Chronic heart failure 
CKD  =  Chronic kidney disease 
CrCl =  Creatinine  clearance 
Cu,Zn-SOD  =  Cu,Zn superoxide dismutase 
GPx =  Glutathione  peroxidase 
GSH =  Glutathione 
Hb =  Hemoglobin 
i.v. =  Intravenous 
ID =  Iron  deficiency 
IDA  =  Iron deficiency anemia 
IL6 =  Interleukin-6 
ISORIG =  Iron  sucrose  originator 
ISS  =  Iron sucrose similar 
ISSBACK  =  Iron sucrose similar Fe-Back 
ISSENCI  =  Iron sucrose similar Encifer
® 
ISSFERI  =  Iron sucrose similar Ferijet 
ISSFERO  =  Iron sucrose similar Ferosoft
®-S 
ISSFERP  =  Iron sucrose similar Ferplex
® SS 
ISSLIB  =  Iron sucrose similar Fe-Lib 
NTBI  =  Non-transferrin bound iron 
RBC  =  Red blood cell 
SBP  =  Systolic blood pressure 
TBARS  =  Thiobarbituric acid reactive species 
TNF-  =  Tumor necrosis factor-alpha 
TSAT =  Transferrin  saturation 
USP  =  The United States Pharmacopeia 
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